Publications by the researcher in collaboration with José Alberto Miranda Filloy (85)

2021

  1. Body mass index and disease activity in chronic inflammatory rheumatic diseases: Results of the cardiovascular in rheumatology (CARMA) project

    Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

2019

  1. Identification of a 3′-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study

    Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 351-360

2017

  1. Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis

    Scientific Reports, Vol. 7

  2. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project

    Journal of Clinical Lipidology, Vol. 11, Núm. 3, pp. 749-756.e3

2016

  1. Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis

    Scientific Reports, Vol. 6

2015

  1. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients

    Rheumatology International, Vol. 35, Núm. 12, pp. 2069-2078

  2. Erratum to "Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project" [Semin Arthritis Rheum 44 (2015) 618-626]

    Seminars in Arthritis and Rheumatism

  3. Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis

    BioMed Research International, Vol. 2015

  4. Protective role of the interleukin 33 rs3939286 gene polymorphism in the development of subclinical atherosclerosis in rheumatoid arthritis patients

    PLoS ONE, Vol. 10, Núm. 11

2014

  1. Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis

    BioMed Research International, Vol. 2014

  2. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients

    Annals of the Rheumatic Diseases

  3. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 2, pp. 231-236

  4. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 2, pp. 218-224

  5. IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy

    BioMed Research International, Vol. 2014

  6. Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis

    Journal of Rheumatology, Vol. 41, Núm. 3, pp. 429-436

  7. Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis

    Arthritis Research and Therapy, Vol. 16, Núm. 4

  8. Investigation of a PON1 gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis

    Annals of the Rheumatic Diseases

  9. Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis

    Mediators of Inflammation, Vol. 2014

  10. Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis

    PLoS ONE, Vol. 9, Núm. 9

  11. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 5, pp. 640-646